Circulating "LncPPAR?" From Monocytes as a Novel Biomarker for Coronary Artery Diseases.
Ontology highlight
ABSTRACT: To investigate long noncoding RNA NONHSAT112178 (LncPPAR?) as a biomarker for coronary artery disease (CAD) in peripheral blood monocyte cells, RT-qPCR was performed to validate the microarray results, receiver operating characteristic curve was applied to study the potential of LncPPAR? as a biomarker. Diagnostic models from LncPPAR? alone or combination of risk factors were constructed by Fisher criteria. The expression of genes neighboring the LncPPAR? gene was examined with RT-qPCR in THP-1 cell line treated with LncPPAR? siRNA. Using a diagnostic model by Fisher criteria, the consideration of risk factors increased the optimal sensitivity from 70.00% to 82.00% and decreased the specificity from 94.00% to 78.00%. The consideration of risk factors also increased area under the receiver operating characteristic curve from 0.727 to 0.785 (P?=?0.001), from 0.712 to 0.768 (P?=?0.01), and from 0.769 to 0.835 (P?=?0.07), in the original, training, and test sets, respectively. Finally, we found that the expression of peroxisome proliferator-activated receptor ? (PPAR?), Adipose Differentiation-Related Protein (ADRP), and Angiopoietin-like 4 (ANGPTL4) were affected by LncPPAR? silencing.Our present study indicated that LncPPAR?, especially combined with risk factors, can be a good biomarker for CAD. LncPPAR? regulates the expression of neighboring protein-coding genes, PPAR? and its direct target genes ADRP and ANGPTL4.
SUBMITTER: Cai Y
PROVIDER: S-EPMC4753863 | biostudies-literature | 2016 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA